PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents yoy growth 0.75-0.9x RVPH's 95.93%. Bill Ackman might demand clarity on why growth lags the competitor's liquidity build.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Cash + STI yoy 0.75-0.9x RVPH's 95.93%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Similar yoy growth to RVPH's 72.84%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-6.11%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-0.83%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Similar yoy to RVPH's 64.40%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
-6.24%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-14.04%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
36.75%
Similar yoy changes to RVPH's 45.49%. Walter Schloss sees parallel capital-raising strategies.
-4.17%
1.25-1.5x RVPH's -3.55%. Bruce Berkowitz notes stronger reinvestment strategy.
-5.37%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
105.08%
1.25-1.5x RVPH's 89.71%. Bruce Berkowitz notes an above-average equity expansion.
67.39%
Similar yoy to RVPH's 64.40%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Similar yoy changes to RVPH's -102.37%. Walter Schloss sees parallel net leverage strategies.